SUPN
Supernus Pharmaceuticals Inc
42.70$
-1.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.3% | 27.4% | 26.7% | 21.2% | 30.5% | 25.5% | 20.4% | 35.4% | -32.1% | 9.4% | 32.0% | -2.2% | 2.4% | |
| 14.2% | 13.2% | 14.4% | 12.3% | 11.4% | 10.8% | 13.6% | 12.9% | 12.9% | 43.6% | 12.6% | 11.7% | 20.3% | |
| 5.1% | 3.9% | 4.1% | 3.9% | 4.4% | 4.4% | 5.4% | 4.5% | 4.1% | 15.6% | 4.1% | 3.9% | 7.0% | |
| 19.3% | 1.2% | 9.7% | -1.7% | -4.5% | -2.9% | 9.3% | 6.9% | -25.6% | -24.3% | 10.5% | -1.3% | -9.8% | |
| 0.1% | 0.0% | 0.2% | 0.0% | 0.1% | 0.1% | 0.2% | 0.3% | 0.1% | 0.2% | 0.0% | 0.3% | 0.1% | |
| 22.5% | -40.2% | -35.9% | -28.9% | -43.8% | -7.3% | 24.9% | -18.5% | 25.4% | -24.3% | -9.3% | 3.2% | -1.8% | |
| -0.1% | -1.2% | -0.9% | 0.0% | 0.8% | – | – | – | – | – | – | – | – | |
| – | – | – | – | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| -0.1% | 0.7% | 1.1% | 1.0% | 1.8% | 3.4% | -14.3% | 0.6% | 11.0% | 4.0% | 4.4% | -3.3% | 3.8% | |
| 45.7% | -12.1% | -8.1% | -6.7% | -11.6% | 21.6% | 31.0% | 17.4% | 4.2% | -10.8% | 27.2% | -2.2% | 4.4% | |
| 23.2% | 27.4% | 26.6% | 21.1% | 30.3% | 25.4% | 20.2% | 35.1% | -32.2% | 9.2% | 32.0% | -2.5% | 2.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.